HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD)
Lauri M. Burroughs(Fred Hutch Cancer Center), David G. Maloney(Fred Hutch Cancer Center), Dietger Niederwieser(Leipzig University of Applied Sciences), Thomas R. Chauncey(City Of Hope National Medical Center), Wendy M. Leisenring(The University of Texas MD Anderson Cancer Center), Richard T. Maziarz(Oregon Health & Science University), Brenda M. Sandmaier(University of Washington), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter A. McSweeney(Mesoblast (United States)), E.D. Agura, M.-T. Little(Fred Hutch Cancer Center), Karl G. Blume(City Of Hope National Medical Center), Michael B. Maris(Colorado Blood Cancer Institute), Monic J. Stuart(United States Department of Veterans Affairs)
Cited by 16
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k